Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on localized cancer reduction and anti-cancer immune activation. The company develops a unique product from its DfuseRx SM discovery platform, which involves direct injection into tumors. This intratumoral (IT) treatment aims to contain drugs within a tumor without systemic spread. The company addresses the challenge that a tumor's microenvironment, characterized by its stromal, high-fat, dense, poorly vascularized, and pressurized nature, does not absorb water-based products. Intensity Therapeutics believes this drug delivery challenge limits the effectiveness of prior IT treatments. The company has developed a product candidate designed to overcome this local delivery challenge within the tumor. Evidence suggests the mechanism of tumor killing achieved by its drug candidate also leads to systemic immune activation and T-cell repertoire expansion in certain cancers. The DfuseRx SM platform creates patented anti-cancer product candidates composed of active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have components soluble in both water and fat/oils. When mixed with therapeutic agents, these agents also become soluble in both fat and water. The company's product candidates are novel formulations combining potent anti-cancer drugs with these amphiphilic agents.